Back to News & Events

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide versus other Glucagon-Like Peptide-1 Receptor Agonists

Share this

About this Poster:

Efpeglenatide is a long-acting GLP-1 R agonist in development for the treatment of type 2 diabetes. Efpeglenatide’s effects on the GLP-1 R suggest that it is a superagonist: a ligand that leads to greater maximal signalling and stimulation compared with the endogenous ligand.

Your development journey
starts with a conversation.

ProSciento
Privacy Overview

More information about our Privacy Policy can be found here.